Bispecific oligonucleotides may induce interferon expression in LNCaP cells enhancing surface antigen expression: Effect of intrastrand base pair complementarity

In Vivo

Volumn 25, Issue 1, 2011, Pages 61-67

  Rubenstein, Marvin ^a,b,c   Hollowell, Courtney M P ^b   Guinan, Patrick ^a,b,c,d  

^a Hektoen Institute for Medical Research   (United States)

^b Jr Hospital of Cook County   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Antisense; Interferon; LNCaP cells; Oligonucleotides; Prostate cancer; Surface antigen

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA INTERFERON; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN BCL 2;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ANTISENSE THERAPY; ARTICLE; BASE PAIRING; CANCER GENE THERAPY; CANCER INHIBITION; CELL LEVEL; CELL STRAIN LNCAP; CONTROLLED STUDY; CYTOKINE RESPONSE; DNA STRAND; DRUG EFFECT; DRUG SPECIFICITY; DRUG TARGETING; MOLECULARLY TARGETED THERAPY; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN INDUCTION; VIRUS IMMUNITY;

EID: 79952018122     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer Statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Dejucq N and Jégou B: Viruses in the mammalian male genital tract and their effects on the reproductive system. Microbiol Mol Biol Rev 65: 208-231, 2001. (Pubitemid 32538178)
3. Matsumoto M and Seya T: TLR3: interferon induction by double-stranded RNA including poly(I:C). Adv Drug Deliv Rev 60: 805-812, 2008.
4. Rubenstein M and Guinan P: Bispecific antisense oligonucleotides have activity comparable to monospecifics in inhibiting expression of BCL-2 in LNCaP cells. In Vivo 24: 489-493, 2010.
5. Basham TY, Nickoloff BJ, Merigan TC and Morhenn VB: Recominant gamma interferon induced HLA-DR expression on cultered human keratinocytes. J Invest Derm 83: 88-90, 1984. (Pubitemid 14054909)
6. Msujimoto M, Yip YK and Vilcek J: Interferon-gamma enhances expression of cellular receptors for tumor necrosis factor. J Immunol 136: 2441-2444, 1986. (Pubitemid 16136820)
7. Lubaroff DM, Konety BR, Link BK, Ratliff T, Madsen T and Williams RD: Outcomes from a phase I trial of an adenovirus/PSA vaccine for prostate cancer. J Urol 179 (suppl): p184 (Abstract 526), 2008.
8. Rubenstein M, Tsui P and Guinan P: Bispecific antisense oligonucleotides with multiple binding sites for the treatment of prostate tumors and their applicability to combination therapy. Methods Find Clin Pharmacol 28: 515-518, 2006. (Pubitemid 44885380)
9. Rubenstein M, Tsui P and Guinan P: Combination chemotherapy employing bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and BCL-2 for the treatment of prostate cancer. Med Oncol 24: 372-378, 2007.
10. Rubenstein M, Tsui P and Guinan P: Multigene targeting of signal transduction pathways for the treatment of breast and prostate tumors. Comparisons between combination therapies employing bispecific oligonucleotides with either rapamycin or paclitaxel Med Oncol 26: 124-130, 2009.
11. Rubenstein M, Tsui P and Guinan P: Bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and BCL-2 for the treatment of prostate tumors. Med Oncol 24: 189-196, 2007. (Pubitemid 350135970)
12. Rubenstein M, Tsui P and Guinan P: Treatment of MCF-7 breast cancer cells employing mono- and bispecific antisense oligonucleotides having binding specificity towards proteins associated with autocrine regulated growth and BCL-2. Med Oncol 25: 182-186, 2008.
13. Rubenstein M, Hollowell CMP and Guinan P: Inhibition of BCL-2 by antisense oligonucleotides is followed by a compensatory suppression of caspase-3 in LNCaP cells. In press: Eur J Clin Med Oncol.
14. McNicol PJ and Dodd JG: Detection of papillomavirus DNA in human prostatic tissue by Southern blot analysis. Can J Microbiol 36: 359-362, 1990. (Pubitemid 20239603)
15. Rapp F, Geder L, Murasko D, Lausch R, Ladda R, Huang ES and Webber MM: Long-term persistence of cytomegalovirus genome in cultured human cells of prostatic origin. J Virol 16: 982-990, 1975.
16. Geder L and Rapp F: Herpesviruses and prostate carcinogenesis. Arch Androl 4: 71-78, 1980. (Pubitemid 10162869)
17. Boldogh I, Baskar JF, Mar EC and Huang ES: Human cytomegalovirus and herpes simplex type 2 virus in normal and adenocarcinomatous prostate glands. JNCI 70: 819-826, 1983. (Pubitemid 13101478)
18. McKay TC, Albala DM, Sendelbach K and Gattuso P: Cytomegalovirus prostatitis. Case report and review of the literature. Int Urol Norphrol 26: 535-540, 1994.
19. Grinstein S, Preciado MV, Gattuso P, Chabay PA, Warren WH, de Matteo E and Gould E: Demonstration of Epstein-Barr virus in carcinomas of various sites. Cancer Res 62: 4876-4878, 2001.
20. Monini P, de Lellis L, Fabris M, Rigolin F and Cassai E: Kaposi's sarcoma-associated herpesvirus DNA sequences in prostate tissue and human semen. N Engl J Med 334: 1168-1172, 1996.
21. Anderson KM, Rubenstein M and Seed TM: in vivo expression of a C-type RNA virus in rat ventral prostate epithelial cells. Biochem Biophys Res Commun 186: 402-406, 1979.
22. Seed TM, Rubenstein M and Anderson KM: Early effects of castration and replacement of androgen on the expression of retrovirus-like particles in rat ventral prostate epithelial cells. Proc Soc Exp Biol Med 169: 470, 1982.